Next week, on NACDS RxIMPACT Day on Capitol Hill, NACDS members and pharmacy advocates will push for PBM reform in-person to Congress and the Biden Administration.
Biktarvy is the first and only INSTI-Based Single-Tablet regimen that is FDA approved and DHHS Guideline Recommended for people who are virologically suppressed with M184V/I resistance.
Congress’ failure to enact PBM reforms for Americans in Medicare and Medicaid and for their pharmacies is nothing short of a wasted opportunity, pharmacy groups said.
The first panel at Drug Store News’ 25th annual Industry Issues Summit explored how retailers and pharmacy technology companies are changing the healthcare experience.